New evidence of reduced risk of modern tobacco consumption
Switching to IQOS poses a lower risk of harm compared to smoking classic cigarettes, according to a six-month clinical study by Philip Morris (PMI) conducted in the United States.
As published, this is the first clinical study that directly measures the body's response to aerosol exposure caused by the use of IQOS, a product that heats rather than burns tobacco.
The study, which is available to both professionals and the general public, measured a range of eight primary and numerous secondary parameters, which are negatively affected by smoking and which are related to diseases caused by smoking.
The results showed that all eight primary clinical risk parameters in people who switched to this cigarette substitute moved in the same direction as in people who quit smoking.